SEC Tracker
Get the app

STAAR Surgical STAA

Staar Surgical reported $5.58 million net income for Q3 2026.

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $83.41 million for the three months ended Oct 2, 2026
  2. Net income: $5.58 million for the three months ended Oct 2, 2026
  3. Diluted EPS: $0.11 for the three months ended Oct 2, 2026
  4. Cash and equivalents: $133.61 million at Oct 2, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when STAAR Surgical files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The statements of operations list net sales of $83,411 thousand for the three months ended October 2, 2026, against $94,732 thousand for the three months ended September 26, 2025.
  2. Gross profit was $59,135 thousand, and operating income was $5,459 thousand.
  3. Net income was $18,839 thousand, against a net loss of $62,139 thousand a year earlier.
  4. Diluted earnings per share were $0.37, against a loss of $1.26.
  5. Merger transaction and related costs were $6,743 thousand for the nine months, and restructuring, impairment and related charges were $2,681 thousand.
  6. The balance sheet shows cash and cash equivalents of $133,610 thousand at October 2, 2026, compared with $153,150 thousand at January 2, 2026.
  7. Total assets were $485,156 thousand, total liabilities $109,027 thousand and total stockholders' equity $376,129 thousand.

7 of 9 claims matched the filing text.

Not found in the filing text

  • For the nine months ended October 2, 2026, net sales were $270,468 thousand, compared with $181,641 thousand for the nine months ended September 26, 2025.
  • In the prior-year nine months, these were $5,926 thousand and $27,938 thousand.

From the filing's financial data, not stated in its text

From this 10-Q's financial data (XBRL) for the quarter ended October 2, 2026

  • For the quarter, the financial statements show revenue of $83.4 million and net income of $5.6 million, with a revenue change from a year earlier of -12.0%.
  • Gross margin was 70.9% and operating margin 6.5%.

From the filing

Item 1. Financial statements

STAAR SURGICAL COMPANY CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value amounts) (Unaudited)
October 2, 2026January 2, 2026
ASSETS
Current assets:
Cash and cash equivalents6$6133,6106$6153,1506
Investments available for sale (amortized cost basis of $72,919 and $34,385 at October 2, 2026 and January 2, 2026, respectively)72,80434,386
Accounts receivable trade, net of allowance for credit losses of $720 and $83 at October 2, 2026 and January 2, 2026, respectively86,52850,064
Inventories, net45,01755,496
Prepayments, deposits and other current assets15,47118,449
Total current assets353,430311,545
Property, plant and equipment, net68,52573,323
Operating lease right-of-use assets, net26,16329,609
Cloud-based software33,06330,700
Goodwill1,7861,786
Deferred income taxes1,0303,365
Other assets1,1591,350
Total assets7$7485,1567$7451,6787
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable$14,249$11,574
Obligations under operating leases5,9435,872
Allowance for sales returns10,22310,199
Other current liabilities45,12640,859
Total current liabilities75,54168,504
Obligations under operating leases27,70132,481
Asset retirement obligations4545
Deferred rent8989
Pension liability5,6516,375
Total liabilities7109,0277107,4947
Commitments and contingencies (Note 12)
Stockholders' equity:
Common stock, $0.01 par value; 60,000 shares authorized: 50,577 shares issued and 50,201 shares outstanding at October 2, 2026 and 49,779 shares issued and 49,403 shares outstanding at January 2, 2026506498
Additional paid-in capital517,381504,682
Treasury stock, 376 and 376 shares at October 2, 2026 and January 2, 2026, respectively(6,461)(6,461)
Accumulated other comprehensive loss(6,112)(6,511)
Accumulated deficit(129,185)(148,024)
Total stockholders' equity7376,1297344,1847
Total liabilities and stockholders' equity$485,156$451,678

See accompanying notes to the condensed consolidated financial statements.

STAAR SURGICAL COMPANY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts) (Unaudited)
Three Months EndedNine Months Ended
October 2, 2026September 26, 2025October 2, 2026September 26, 2025
Net sales1$183,4111$194,7321$1270,4681$1181,6411
Cost of sales24,27616,85772,74742,962
Gross profit259,135277,8752197,7212138,6792
Selling, general and administrative expenses:
General and administrative18,89920,76358,66066,190
Selling and marketing24,31623,46175,76976,689
Research and development10,4619,20930,32930,811
Merger transaction and related costs5—55,92656,74355,9265
Restructuring, impairment and related charges5—52652,681527,9385
Total selling, general and administrative expenses53,67659,385174,182207,554
Operating income (loss)25,459218,490223,5392(68,8752)2
Other income (expense), net:
Interest income, net1,1757903,0213,522
Gain (loss) on foreign currency transactions(42)(843)(1,563)3,138
Other income, net3883531,225604
Total other income, net1,5213002,6837,264
Income (loss) before income taxes6,98018,79026,222(61,611)
Provision for income taxes1,4059,9067,383528
Net income (loss)3$35,5753$38,8843$318,8393$3(62,1393)3
Net income (loss) per share:
Basic$0.11$0.18$0.37$(1.26)
Diluted4$40.114$40.184$40.374$4(1.264)4
Weighted average shares outstanding:
Basic50,54249,63350,25749,499
Diluted51,44950,54951,40249,499

See accompanying notes to the condensed consolidated financial statements.

STAAR SURGICAL COMPANY CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands) (Unaudited)
Three Months EndedNine Months Ended
October 2, 2026September 26, 2025October 2, 2026September 26, 2025
Net income (loss)$5,575$8,884$18,839$(62,139)
Other comprehensive income (loss):
Defined benefit plans:
Net change in plan assets876(514)764(184)
Reclassification into other income (expense), net(6)17(18)49
Investments available for sale:
Change in unrealized gain (loss)(101)3(117)11
Reclassification into other income (expense), net—1—2
Foreign currency translation gain (loss)244(639)(238)866
Tax effect(158)2508(240)
Other comprehensive income (loss), net of tax855(882)399504
Comprehensive income (loss)$6,430$8,002$19,238$(61,635)

See accompanying notes to the condensed consolidated financial statements.

STAAR SURGICAL COMPANY CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

(In thousands) (Unaudited)
Three Months Ended
Common
Stock Shares
Common
Stock Par
Value
Additional
Paid-In
Capital
Treasury Stock Shares
Treasury Stock
Accumulated
Other
Comprehen- sive Income
(Loss)
Accumulated
Deficit
Total
Balance, at July 3, 202650,499$505$513,081(376)$(6,461)$(6,967)$(134,760)$365,398
Net income——————5,5755,575
Other comprehensive income—————855—855
Stock-based compensation——5,620————5,620
Repurchase of employee common stock for taxes withheld(53)—(1,320)————(1,320)
Vested restricted and performance stock units1311—————1
Balance, at October 2, 202650,577$506$517,381(376)$(6,461)$(6,112)$(129,185)$376,129
Balance, at June 27, 202549,546$495$484,801(261)$(4,479)$(5,645)$(138,599)$336,573
Net income——————8,8848,884
Other comprehensive loss—————(882)—(882)
Common stock issued upon exercise of options15712,963————2,964
Stock-based compensation——8,222————8,222
Repurchase of common stock———(115)(1,982)——(1,982)
Repurchase of employee common stock for taxes withheld(2)———————
Vested restricted and performance stock units291—————1
Balance, at September 26, 202549,730$497$495,986(376)$(6,461)$(6,527)$(129,715)$353,780

See accompanying notes to the condensed consolidated financial statements.

STAAR SURGIC

Similar companies

Companies of similar size in SIC 3851 and related industry codes: the same peer list as the financial tables.

  1. National Vision Holdings EYE public float $1.3B, Jun 28, 2025
  2. Bausch & Lomb BLCO public float $557M, Jun 30, 2025
  3. RxSight RXST public float $504M, Jun 30, 2025
  4. Warby Parker WRBY public float $2.2B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.